A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

NCT06703892 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma Relapsed
Diffuse Large B Cell Lymphoma Refractory
Follicular Lymphoma ( FL)
Primary Mediastinal Large B-Cell Lymphoma-Refractory
Primary Mediastinal Large B-Cell Lymphoma-Recurrent
High-grade B-cell Lymphoma (HGBCL)

Interventions

BIOLOGICAL: GF-CART01
BIOLOGICAL: GF-CART01
BIOLOGICAL: GF-CART01

Sponsor

GenomeFrontier Therapeutics TW Co., Ltd.